Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy

2 Jan 2017

Abstract excerpt

Recombinant adeno-associated virus (rAAV) is a commonly used gene therapy vector for the delivery of therapeutic transgenes in a variety of human diseases, but pre-existing serum antibodies to viral capsid proteins can greatly inhibit rAAV transduction of tissues. Serum was assayed from patients with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), inclusion body myositis (IBM), and GNE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Muscle Physiology and Disorders
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28042944
DOI: 10.1089/hum.2016.141

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE MyopathyPMID 28042944Read ↗

Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular DystrophySemantic proximity Read ↗

Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate ModelSemantic proximity Read ↗

Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disordersSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across speciesSemantic proximity Read ↗

Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular DystrophySemantic proximity Read ↗

Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human TrialsSemantic proximity Read ↗

Progress in Bioengineering of Myotropic Adeno-Associated Viral Gene Therapy VectorsSemantic proximity Read ↗

B-cell depletion is protective against anti-AAV capsid immune response: a human subject case studySemantic proximity Read ↗

Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical StudiesSemantic proximity Read ↗

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible SolutionsSemantic proximity Read ↗

Quantification of CpG Motifs in rAAV Genomes: Avoiding the TollSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.